PAPontus Andell

Pontus Andell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pontus Andell has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes after a first acute myocardial infarction in patients with or without congenital heart disease

    by Love Holmgren, Sacharias von Koch, Pontus Andell, Peder Sörensson, Christina Christersson, Aleksandra Trzebiatowska-Krzynska, Maria Fedchenko, Zacharias Mandelanakis, Bengt Johansson, Moman A Mohammad, et al.

    The life expectancy of adult patients with congenital heart disease (ACHD) has improved, thus shifting the research focus towards age-related comorbidities to continue to improve patient outcomes. This study aimed to investigate all-cause mortality and recurrent acute myocardial infarction (AMI) in adults with and without congenital heart disease. A nationwide case control study was conducted between 2000 and 2022. Patients with ACHD (n = 214) and controls (n = 275 377) who experienced their first AMI were identified. Of these, each patient (n = 213) with ACHD was matched with 10 controls (n = 2092) based on age, sex, hypertension, diabetes, hyperlipidaemia, and history of percutaneous coronary intervention or coronary artery bypass grafting. Mortality and recurrent AMI were assessed using unadjusted and adjusted Cox regression for matching and other clinical covariates. Patients with ACHD were younger (58 ± 14 years) than controls (70 ± 12 years) before the matching (P < .001). The mean follow-up time was 6.5 and 7.3 years for patients with ACHD and controls, respectively. There was no significant difference in mortality or recurrent AMI rates at 1 year between patients with ACHD and matched controls. The mortality rate was higher in ACHD at 10 years of follow-up (hazard ratio 1.4, 95% confidence interval 1.0–1.9) but did not remain after adjustment. This study suggests that survival rates and the incidence of recurrent AMI in ACHD patients are similar to those of controls. Since patients with ACHD share similar cardiovascular risk factors as the general population, promoting healthy lifestyles and proactive risk management is crucial to mitigate acquired heart disease. Flowchart showing the inclusion of all patients aged ≥18 years who had their first-time acute myocardial infarction (AMI) recorded in SWEDEHEART between 1 January 2000 and 2 February 2022. Cumulative risk of first AMI in 214 patients with adult congenital heart disease (ACHD) and 257,377 controls (Log rank < 0.05). Kaplan-Meier survival graph of mortality in 213 patients with ACHD and 2,092 matched controls who had an AMI between 2000 and 2022 (Log rank p = 0.81).


  • Open Access

    Development and external validation of machine learning approaches for risk prediction of cardiovascular disease in individuals with schizophrenia: a nationwide Swedish and Danish study

    by Sara Dorthea Nielsen, Maja Dobrosavljevic, Pontus Andell, Zheng Chang, Line Katrine Harder Clemmensen, Henrik Larsson, Michael Eriksen Benros

    Background: Currently available cardiovascular disease (CVD) risk prediction tools may underestimate the risk in individuals with schizophrenia. Objective: To develop and externally validate 5-year CVD risk prediction models for people with schizophrenia using large-scale register data in Sweden and Denmark with a machine learning (ML) approach. Methods: Individuals with a diagnosis of schizophrenia, aged 30 and older and without prior CVD, were followed for up to 5 years. We investigated whether adding additional health-related and socio-demographic predictors to the established CVD risk factors improved predictions and compared ML models with logistic regression. External validation was performed across countries. Findings: A lasso penalised logistic regression including additional predictors achieved the highest predictive performance, both on Swedish and Danish data, while complex ML models with interaction terms did not provide additional improvements. The area under the receiver operating characteristic curve (AUC) on the internal validation data was 0.745 (95% CI (0.742 to 0.749)) in the Swedish model, and 0.722, 95% CI (0.719 to 0.726) in the Danish model. External validation showed similar performance, yielding an AUC of 0.746, 95% CI (0.741 to 0.751) using the Danish model on the Swedish data, and an AUC of 0.720, 95% CI (0.712 to 0.726) using the Swedish model on the Danish validation data. Conclusions: Incorporating additional health-related information, such as psychiatric comorbidities and medication use, improved 5-year CVD risk prediction for people with schizophrenia in both countries. Clinical implications: The models can be deployed between Denmark and Sweden without loss of performance compared with training a model on each country.


  • Open Access

    A five-year risk prediction model of cardiovascular disease in individuals with bipolar disorder: a nationwide register study from Sweden

    by Maja Dobrosavljevic, Mikael Landén, Isabell Brikell, Zheng Chang, Ralf Kuja-Halkola, Paul Lichtenstein, Pontus Andell, Ole A. Andreassen, Michael Bauer, Rosa Corcoy, et al.

    Cardiovascular disease (CVD) risk prediction models for the general population may not provide accurate predictions in individuals with bipolar disorder (BD) who have elevated risks of cardiometabolic conditions and premature mortality. Therefore, we aimed to: 1) develop a five-year CVD risk prediction model in this population by using nationwide register data from Sweden, 2) investigate whether the performance improved when we considered additional risk factors, including psychiatric comorbidity, psychotropic medication, and socio-demographic variables, compared to using established CVD risk factors only, and 3) whether machine learning approach provided improvements compared to standard logistic regression models. We followed 33,933 persons with BD aged 30–82 years old, without previous CVD, from the date of BD diagnosis registered between 2007–2014, for up to five years. The logistic regression model containing only established risk factors yielded an area under the receiver operating characteristic curve (AUC) of 0.76 (95% confidence interval 0.74–0.78) in the test dataset, while the logistic regression model and the best performing machine learning model including additional predictors yielded similar results (AUC was 0.77 (0.75, 0.79) in both models). The performance of logistic regression models slightly improved with additional predictors when continuous risk scores were used. In conclusion, standard logistic regression and established CVD risk factors may be sufficient to predict CVD in individuals with BD when using population register-based data from Sweden. External validation across diverse healthcare settings and rigorous assessment of clinical impact will be crucial next steps before implementing these models in clinical practice.


  • Open Access

    Trends in risk factors among young patients with acute myocardial infarction: a nationwide cohort study

    by Moa Simonsson, Moman A Mohammad, Sofia Sederholm Lawesson, Robin Hofmann, Jonas Faxén, David Erlinge, Christian Reitan, Pontus Andell

    Aims: Acute myocardial infarction (AMI) is associated with significant loss-of-life expectancy, particularly among younger females. Addressing risk factors is crucial for optimizing prevention strategies. The aim of this study was to describe the trends in risk factors and clinical outcomes in a nationwide cohort of young AMI patients stratified by sex. Methods and results: Using Swedish registries, we included AMI patients aged 18–59 and selected five matched non-AMI controls from the general population. Risk factors included hypertension, diabetes, chronic kidney disease, hyperlipidaemia, obesity, smoking and systemic inflammatory disease. Clinical outcomes were major adverse cardiovascular events (death, AMI, stroke, or heart failure) and bleeding events. From 2006 to 2021, 44 254 AMI cases (9602 females and 34 652 males) and 220 721 non-AMI controls (47 967 females and 172 754 males) were included. Among AMI cases, the prevalence of at least one risk factor was higher in females than males (78.9 vs. 73.7%). Obesity increased from 25.2 to 35.5% becoming the most common risk factor. The risk of clinical outcomes was higher in cases than controls and in females compared with males among the cases, but lower among females compared with males among the controls. Five-year mortality was 6.1 vs. 1.3% in females and 4.9 vs. 1.8% males (cases vs. controls). Conclusion: Three in four young AMI patients have at least one known risk factor, of which obesity is the most common. Risk factor burden and clinical outcomes are worse among females. Prevention strategies and enhanced follow-up for young AMI patients should be prioritized. Further studies are needed to investigate sex-specific risk factors.


  • Open Access

    Attention-deficit/hyperactivity disorder and cardiometabolic risk profile in patients with acute myocardial infarction: data from the SWEDEHEART registry

    by Honghui Yao, Isabell Brikell, Henrik Larsson, Lin Li, Ebba Du Rietz, Catharina A Hartman, Tomas Jernberg, Pontus Andell, Zheng Chang

    Aims: Attention-deficit/hyperactivity disorder (ADHD) is increasingly diagnosed in adults and is associated with cardiometabolic diseases. Yet, the associations between ADHD and cardiometabolic risk profile, participation in non-pharmacological interventions, and long-term outcomes in patients with myocardial infarction (MI) remain unclear. Methods and results: This observational study involved patients from the SWEDEHEART (the Swedish Web-system for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapy) registry, aged 18–74 years old, diagnosed with their first acute MI from 2006 to 2020. We assessed the associations between ADHD and cardiometabolic risk profile (clinical parameters, disease histories, and behavioural factors), engagement in guideline-recommended non-pharmacological interventions, recurrent cardiovascular events, and mortality. We analysed adults with MI with ADHD (n = 582) and without ADHD (n = 2704). Most clinical parameters and disease histories did not differ significantly between groups. However, patients with ADHD had higher risks of smoking (risk ratio, RR = 1.53; 95% confidence interval 1.36–1.71] and snus use (RR = 1.65; 1.36–1.99), were less likely to participate in follow-up evaluations (RR = 0.87; 0.79–0.96), or to stop smoking after MI (RR = 0.76; 0.63–0.91). They had a higher rate of all-cause mortality (hazard ratio = 2.02; 1.05–3.88) after discharge, but not recurrent cardiovascular events. Conclusion: Adults with MI and ADHD present similar cardiometabolic risk profiles but poorer lifestyle behaviours, lower engagement in recommended interventions, and higher mortality compared with those without ADHD, underscoring the need for integrated cardiology care with psychiatric services.


  • Open Access

    Increased risk of acute myocardial infarction in Swedish patients with systemic sclerosis: a population-based study

    by Majd Bairkdar, Karina Patasova, Pontus Andell, Marie Holmqvist

    Objectives: To study the risk of acute myocardial infarction (AMI) in patients with SSc in a population-based cohort. Methods: Using nationwide Swedish registers, we identified patients with incident SSc 2004–19 and age- and sex-matched comparators from the general population (1:10). Our primary outcome was incident AMI or death from incident AMI. We started follow-up from SSc diagnosis until the primary outcome, death from other cause than AMI, emigration or study end (31 December 2019). We estimated crude AMI incidence rate. We used flexible parametric models to explore the relative risk of AMI over time since diagnosis. We also used age as time scale to explore how AMI risk changes over increasing age. We also studied the outcomes of AMI in SSc compared with the matched comparators. Results: We identified 1579 patients and 16 064 comparators. The incidence rate of AMI was 75.2 (95% CI 58.8–94.6) per 10 000 person-years in patients with SSc and 37.5 (95% CI 34.0–41.3) in the comparators, median follow-up was 5.2 and 6.3 years, respectively. The adjusted hazard ratio (HR) was highest during the first year after SSc diagnosis (HR 3.1, 95% CI 2.0–4.6). In patients with SSc, the risk of AMI increased more rapidly with increasing age compared with the comparators. AMI in SSc was associated with higher risk of mortality (HR 2.7, 95% CI 1.6–4.4) but not 30-day readmission (HR 1.3, 95% CI 0.7–2.0) compared with the comparators. Conclusion: In line with previous studies, SSc is associated with a 2-fold increase in AMI incidence compared with the general population.


  • Open Access

    Difficulties in running clinical trials on physical activity

    by Emmanuel A Zavalis, Pontus Andell

    This commentary refers to ‘Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial’, by D.-c. Lee et al., https://doi.org/10.1093/eurheartj/ehad827 and the discussion piece ‘Re-evaluating concurrent training strategies for cardiovascular risk reduction in overweight or obese adults’, by J. Du and J. Hou, https://doi.org/10.1093/eurheartj/ehae583.


  • Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study

    by Christian Reitan, Pontus Andell, Joakim Alfredsson, David Erlinge, Robin Hofmann, Bertil Lindahl, Moa Simonsson, Paul W. Dickman, Tomas Jernberg

    BACKGROUND: The effect of myocardial infarction (MI) on life expectancy is difficult to study because the prevalence of MI hinders direct comparison with the life expectancy of the general population. We sought to assess this in relation to age, sex, and left ventricular ejection fraction (LVEF) by comparing individuals with MI with matched comparators without previous MI. METHODS: We included patients with a first MI between 1991 and 2022 from the nationwide SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies), each matched with up to 5 comparators on age, sex, and region of residence. Flexible parametric survival models were used to estimate excess mortality and mean loss of life expectancy (LOLE) depending on index year, age, sex, and LVEF, and adjusted for differences in characteristics. RESULTS: A total of 335 748 cases were matched to 1 625 396 comparators. A higher LOLE was observed in younger individuals, women, and those with reduced LVEF (<50%). In 2022, the unadjusted and adjusted mean LOLE spanned from 11.1 and 9.5 years in 50-year-old women with reduced LVEF to 5 and 3.7 months in 80-year-old men with preserved LVEF. Between 1992 and 2022, the adjusted mean LOLE decreased by 36% to 55%: from 4.4 to 2.0 years and from 3.3 to 1.9 years in 50-year-old women and men, respectively, and from 1.7 to 1.0 years and from 1.4 to 0.9 years in 80-year-old women and men, respectively. CONCLUSIONS: LOLE is higher in younger individuals, women, and those with reduced LVEF, but is attenuated when adjusting for comorbidities and risk factors. Advances in MI treatment during the past 30 years have almost halved LOLE, with no clear sign of leveling off to a plateau.